Priya Alexander

They have looked at them for three years.

They've looked at things like who has another heart attack, a stroke, death, who goes to hospital.

And what they found is in the group at three years who had that really intensive management push to below 1.4, they did better.

They had less events.

This for me, Norman, as a clinician is a really good reminder to not let therapeutic inertia set in.

And therapeutic inertia is a danger.

It's dangerous stuff.

It's where I see you, Norman, I check your blood pressure and I go, ah, it's a little bit high today.

I might leave it.

We'll check it next time.

You go and see the GP next door who also says, oh, Norman, it's a bit high today, but we'll check it next time.

And no one actually jumps on things and manages it.

So when I saw this, it was a really beautiful reminder that, gosh, get the lipids to target in the people who need it.

It's just another nudge.

The only thing with this study is that it was in East Asian patients only.

So I do wonder if that has an impact.

And the researchers did say that there was a potential limitation of their study.

But, you know, just something to flag.

Yes.

Sorry.